Short-term efficacy and safety of intravitreal ranibizumab for myopic choroidal neovascularization

Retina

Volumn 28, Issue 8, 2008, Pages 1117-1123

  Silva, Rufino M ^a,b   Ruiz Moreno, Josi M ^c,d   Nascimento, João ^e   Carneiro, Ãngela ^f   Rosa, Paulo ^e   Barbosa, Augusto ^a   Carvalheira, Fausto ^a,b   Abreu, J Rui Faria ^a,b   Cunha Vaz, Josi G ^a,b  

^a CENTRO HOSPITALAR E UNIVERSITÁRIO DE COIMBRA   (Portugal)

^b ASSOCIATION FOR INNOVATION AND BIOMEDICAL RESEARCH ON LIGHT AND IMAGE AIBILI   (Portugal)

^c UNIVERSITY OF CASTILLA LA MANCHA   (Spain)

^d Vitreoretinal Unit ^*  (Spain)

^e Institute of Ophthalmology   (Portugal)

^f HOSPITAL DE SÃO JOÃO   (Portugal)

Author keywords

Antiangiogenic drugs; CNV; Lucentis; Myopia; Photodynamic therapy; Ranibizumab; Verteporphin

Indexed keywords

OFLOXACIN; RANIBIZUMAB; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; ENDOPHTHALMITIS; EYE INFLAMMATION; FEMALE; FOLLOW UP; HUMAN; INTERVENTION STUDY; INTRAOCULAR HYPERTENSION; MALE; MULTICENTER STUDY; MYOPIA; OPTICAL COHERENCE TOMOGRAPHY; PATHOLOGIC MYOPIA; PHOTODYNAMIC THERAPY; RETINA DETACHMENT; RETROSPECTIVE STUDY; SUBRETINAL NEOVASCULARIZATION; THERAPY EFFECT; THROMBOEMBOLISM; TREATMENT OUTCOME; TREATMENT RESPONSE; VISUAL ACUITY; DEGENERATIVE MYOPIA; DRUG EFFECT; DRUG SCREENING; INJECTION; MIDDLE AGED; PATHOPHYSIOLOGY; TIME; VITREOUS BODY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; CHOROIDAL NEOVASCULARIZATION; DRUG EVALUATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; INJECTIONS; MALE; MIDDLE AGED; MYOPIA, DEGENERATIVE; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; VISUAL ACUITY; VITREOUS BODY; YOUNG ADULT;

EID: 58149268003     PISSN: 0275004X     EISSN: None     Source Type: Journal    
DOI: 10.1097/IAE.0b013e31817eda41     Document Type: Article

References (18)

1. Avila MP, Weiter JJ, Jalkh AE, Trempe CL, Pruett RC, Schepens CL. Natural history of choroidal neovascularization in degenerative myopia. Ophthalmology 1984;91:1573-1581.
2. Hampton GR, Kohen D, Bird AC. Visual prognosis of disciform degeneration in myopia. Ophthalmology 1983;90:923-926.
3. Tabandeh H, Flynn HW Jr, Scott IU, et al. Visual acuity outcomes of patients 50 years of age and older with high myopia and untreated choroidal neovascularization. Ophthalmology 1999;106:2063-2067.
4. Yoshida T, Ohno-Matsui K, Ohtake Y, et al. Long-term visual prognosis of choroidal neovascularization in high myopia: a comparison between age groups. Ophthalmology 2002;109: 712-719.
5. Verteporfin in Photodynamic Therapy Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin: 1-year results of a randomized clinical trial - VIP report no. 1. Ophthalmology 2001;108:841-852.
6. Verteporfin in Photodynamic Therapy (VIP) Study Group. Verteporfin therapy of subfoveal choroidal neovascularisation in pathologic myopia: 2-year results of a randomized clinical trial - VIP report no. 3. Ophthalmology 2003;110:667-673.
7. Montero JA, Ruiz-Moreno JM. Verteporfin photodynamic therapy in highly myopic subfoveal choroidal neovascularisation. Br J Ophthalmol 2003;87:173-176.
8. Rich RM, Rosenfeld PJ, Puliafito CA, et al. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina 2006;26:495-511.
9. Mandal S, Venkatesh P, Sampangi R, Garg S. Intravitreal bevacizumab (Avastin) as primary treatment for myopic cho-roidal neovascularization. Eur J Ophthalmol 2007;17:620-626.
10. Hernandez-Rojas ML, Quiroz-Mercado H, Dalma-Weiszhausz J, et al. Short-term effects of intravitreal bevacizumab for subfoveal choroidal neovascularization in pathologic myopia. Retina 2007;27:707-712.
11. Ruiz-Moreno JM, Gomez-Ulla F, Montero JA, et al. Intravit-reous bevacizumab to treat subfoveal choroidal neovascular-ization in highly myopic eyes: short-term results. Eye 2007. [epub ahead of print].
12. Rosenfeld PJ. Intravitreal Avastin for choroidal neovascularisation in pathological myopia: the controversy continues. Br J Ophthalmol 2007;91:128-130.
13. Yamamoto I, Rogers AH, Reichel E, Yates PA, Duker JS. Intravitreal bevacizumab (Avastin) as treatment for subfoveal choroidal neovascularisation secondary to pathological myopia. Br J Ophthalmol 2007;91:157-160.
14. Sakaguchi H, Ikuno Y, Gomi F, et al. Intravitreal injection of bevacizumab for choroidal neovascularisation associated with pathological myopia. Br J Ophthalmol 2007;91: 161-165.
15. Chan WM, Lai TY, Liu DT, Lam DS. Intravitreal bevaci-zumab (Avastin) for myopic choroidal neovascularization. Six-month results of a prospective pilot study. Ophthalmology 2007;114:2190-2196.
16. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355:1432-1444.
17. Tong JP, Chan WN, Liu DT, et al. Aqueous humor levels of vascular endothelial growth factor and pigment epithelium-derived factor in polypoidal choroidal vasculopathy and choroidal neovascularization. Am J Ophthalmol 2006;141:456 -462.
18. Rosenfeld PJ, Rich RM, Lalwani GA. Ranibizumab: phase III clinical trial results. Ophthalmol Clin North Am 2006; 19:361-372.